Fortress Biotech, Inc. (FBIO): Long-Term Debt
$52.42M
As of 2025-12-31
$35.00M
As of 2026-06-30
-17.0%
3-year compound annual growth
+0.3%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $52.42M | -9.6% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $57.96M | -4.8% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $60.86M | -33.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $91.73M | +113.6% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $42.94M | -16.9% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $51.68M | -39.0% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $84.66M | n/c | 2021-04-09, Balance as of period end |
| 2018-12-31 | $84.41M | +25.0% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $67.54M | +123.5% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $30.22M | +25.9% | 2018-03-16, Balance as of period end |
| 2015-12-31 | $24.01M | +71.4% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $14.01M | n/a | 2016-03-15, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $52.42M | -9.6% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $47.21M | n/a |
| Journey Medical Corp (DERM) | 2025-12-31 | $25.28M | +1.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $9.70M | +1.9% |
| Eton Pharmaceuticals, Inc. (ETON) | 2024-12-31 | $29.81M | n/a |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $96.37M | n/a |
| Standard Biotools Inc. (LAB) | 2024-12-31 | $299.0K | -99.5% |
| Cytokinetics Inc (CYTK) | 2024-12-31 | $619.52M | -3.1% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $45.00M | 0.0% |
Compare FBIO, NUVB, DERM, KURA side by side · Screen every company in Pharmaceutical Preparations ↗